(R)-N-(1-(2-氟-5-硝基苯)亚乙基)-2-甲基丙烷-2-亚磺酰胺 | 1075230-62-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-N-(1-(2-氟-5-硝基苯)亚乙基)-2-甲基丙烷-2-亚磺酰胺
• 中文别名: [N(E),S(R)]-N-(1-(2-氟-5-硝基苯)亚乙基)-2-甲基丙烷-2-亚磺酰胺
• 英文名称: (R,E)-N-(1-(2-fluoro-5-nitrophenyl)ethylidene)-2-methylpropane-2-sulfinamide
• 英文别名: (NE,R)-N-[1-(2-fluoro-5-nitrophenyl)ethylidene]-2-methylpropane-2-sulfinamide
• CAS: 1075230-62-4
• 化学式: C₁₂H₁₅FN₂O₃S
• 分子量: 286.327
• InChiKey: KAEBKJXUYIZJGX-XOVNIXPASA-N

物化性质

• 沸点：
  416.9±55.0 °C(Predicted)
• 密度：
  1.29±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  94.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (R)-N-(1-(2-氟-5-硝基苯)亚乙基)-2-甲基丙烷-2-亚磺酰胺 在 盐酸 、 potassium osmate(VI) dihydrate 、 伯吉斯试剂 、 sodium methylate 、 4-甲基苯磺酸吡啶 、 铁粉 、 碳酸氢钠 、 氯化铵 、 N-甲基吗啉氧化物 、 三乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 二氯甲烷 、 水 、 乙酸乙酯 、 丙酮 、 甲苯 为溶剂， 反应 17.17h， 生成 (S)-(2-(bis(2,4-dimethoxybenzyl)amino)-4-(2-fluoro-5-(2,2,2-trifluoroacetamido)phenyl)-4-methyl-4H-1,3-oxazin-6-yl)methyl methanesulfonate
  参考文献：
  名称：

  Rational Design of Novel 1,3-Oxazine Based β-Secretase (BACE1) Inhibitors: Incorporation of a Double Bond To Reduce P-gp Efflux Leading to Robust Aβ Reduction in the Brain

  摘要：

  Accumulation of A beta peptides is a hallmark of Alzheimer's disease (AD) and is considered a causal factor in the pathogenesis of AD. beta-Secretase (BACE1) is a key enzyme responsible for producing A beta peptides, and thus agents that inhibit BACE1 should be beneficial for disease-modifying treatment of AD. Here we describe the discovery and optimization of novel oxazine-based BACE1 inhibitors by lowering amidine basicity with the incorporation of a double bond to improve brain penetration. Starting from a 1,3-dihydrooxazine lead 6 identified by a hit-to-lead SAR following HTS, we adopted a pKa lowering strategy to reduce the P-gp efflux and the high hERG potential leading to the discovery of 15 that produced significant A beta reduction with long duration in pharmacodynamic models and exhibited wide safety margins in cardiovascular safety models. This compound improved the brain-to-plasma ratio relative to 6 by reducing P-gp recognition, which was demonstrated by a P-gp knockout mouse model.

  DOI：

  10.1021/acs.jmedchem.8b00002
• 作为产物：
  描述：

  2'-氟苯乙酮 在 titanium(IV) tetraethanolate 、 硫酸 作用下， 以 乙酸乙酯 为溶剂， 反应 18.5h， 生成 (R)-N-(1-(2-氟-5-硝基苯)亚乙基)-2-甲基丙烷-2-亚磺酰胺
  参考文献：
  名称：

  [EN] NOVEL CRYSTALLINE FORMS OF A BACE INHIBITOR, COMPOSITIONS, AND THEIR USE
  [FR] NOUVELLES FORMES CRISTALLINES D'UN INHIBITEUR DE BACE, COMPOSITIONS ET LEUR UTILISATION

  摘要：

  本发明提供了一种新颖的维鲁贝卡斯塔合成方法，以及两种新颖的维鲁贝卡斯塔的晶体形式，以及其药用可接受的组合物，这些组合物可能在治疗、预防、缓解和/或延迟Aβ病理和/或其症状的发生方面有用。本文披露了此类Aβ病理的非限制性示例，包括阿尔茨海默病。

  公开号：

  WO2016025364A1

文献信息

• [EN] C2-AZASPIRO IMINOTHIAZINE DIOXIDES AS BACE INHIBITORS<br/>[FR] DIOXYDES C2-AZASPIRO IMINOTHIAZINES EN TANT QU'INHIBITEURS DE BACE
  申请人：MERCK SHARP & DOHME

  公开号：WO2014150344A1

  公开（公告）日：2014-09-25

  In its many embodiments, the present invention provides certain C2-azaspirosubstituted iminothiazine dioxide compounds. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些C2-氮杂螺取代亚噁唑二氧化物化合物。本发明的新化合物可用作BACE抑制剂和/或用于治疗和预防与之相关的各种病理。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的药物组合物，以及其制备和使用的方法，包括可能用于治疗阿尔茨海默病。
• [EN] PENTAFLUOROSULFUR IMINO HETEROCYCLIC COMPOUNDS AS BACE-1 INHIBITORS, COMPOSITIONS, AND THEIR USE<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES DE TYPE IMINO-PENTAFLUOROSULFURE UTILISÉS EN TANT QU'INHIBITEURS DE BACE1, COMPOSITIONS EN CONTENANT ET LEUR UTILISATION
  申请人：SCHERING CORP

  公开号：WO2011044184A1

  公开（公告）日：2011-04-14

  In its many embodiments, the present invention provides provides certain pentafluorosulfur imino heterocyclic compounds, including compounds Formula (I): and tautomers thereof, and solvates, prodrugs, esters, and deuterates of said compounds and said tautomers, and pharmaceutically acceptable salts of said compounds, tautomers, solvates, prodrugs, esters, and deuterates, wherein each of R1, R2, R3, R4, R5, R9, R11, ring A, ring B, m, n, p, q, r, -L1-,L2-, and L3- is selected independently and as defined herein. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimers Disease, are also disclosed.

  在其多种实施方式中，本发明提供了某些五氟硫代咪唑杂环化合物，包括化合物式（I）：及其互变异构体、溶剂化物、前药、酯类和氘代物以及所述化合物和所述互变异构体的药学上可接受的盐，其中R1、R2、R3、R4、R5、R9、R11、环A、环B、m、n、p、q、r、-L1-、L2-和L3-中的每一个都是独立选择并按本文所定义的。还公开了包括一种或多种这样的化合物（单独和与一种或多种其他活性剂的组合）的药物组合物，以及其制备和在治疗与淀粉样蛋白β（Aβ）蛋白相关的病理学，包括阿尔茨海默病，中的用途的方法。
• Iminothiadiazine Dioxide Compounds as BACE Inhibitors, Compositions and Their Use
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20150307465A1

  公开（公告）日：2015-10-29

  In its many embodiments, the present invention provides certain iminothiadiazine dioxide compounds, including compounds Formula (I): and include stereoisomers thereof, and pharmaceutically acceptable salts of said compounds stereoisomers, wherein each of R 1 , R 2 , R 3 , R 4 , R 5 , R 9 , ring A, ring B, m, n, p, -L 1 -, -L 2 -, and -L 3 - is selected independently and as defined herein. The novel iminothiadiazine dioxide compounds of the invention have surprisingly been found to exhibit properties which are expected to render them advantageous as BACE inhibitors and/or for the treatment and prevention of various pathologies related to β-amyloid (“Aβ”) production. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use in treating pathologies associated with amyloid beta (Aβ) protein, including Alzheimer's disease, are also disclosed.

  本发明提供了多种形式的亚氨基噻二唑二氧化物化合物，包括公式(I)的化合物： 包括它们的立体异构体，以及所述立体异构体的药用可接受盐，其中R1、R2、R3、R4、R5、R9、环A、环B、m、n、p、-L1-、-L2-和-L3-都是独立选择且按本文定义。发明的新型亚氨基噻二唑二氧化物化合物出人意料地被发现具有预期的特性，使其作为BACE抑制剂以及/或用于治疗和预防与β-淀粉样蛋白（“Aβ”）生成相关的各种病理学具有优势。还公开了包含一个或多个此类化合物（单独使用和与一个或多个其他活性成分组合使用）的药物组合物，以及它们的制备方法和用于治疗与淀粉样β（Aβ）蛋白相关的病理学，包括阿尔茨海默病的方法。
• A novel domino reaction for the preparation of substituted non-racemic β-proline derivatives
  作者：Eric J. Gilbert、Andrew Brunskill、Jiaqiang Cai、Yaxian Cai、Xin-Jie Chu、Xing Dai、Jinsong Hao、Jeffrey T. Kuethe、Zhong Lai、Hong Liu、Cuizhi Mu、Yan Qi、Jack D. Scott、Brandon Taoka、Quang Truong、Shawn P. Walsh、Wen-Lian Wu、Jared N. Cumming

  DOI：10.1016/j.tet.2016.08.017

  日期：2016.10

  A novel domino reaction for the preparation of non-racemic β-proline derivatives is reported. The addition of a methyl 2-(oxetan-3-yl)acetate titanium enolate to chiral tert-butanesulfinyl ketimines followed by an intramolecular oxetane ring-opening provides the highly-substituted pyrrolidine ring systems with three contiguous stereogenic centers.

  报道了用于制备非外消旋β-脯氨酸衍生物的新型多米诺反应。在手性叔丁烷亚磺酰基酮亚胺中加入2-（氧杂环丁-3-基）乙酸甲酯烯醇钛，然后分子内氧杂环丁烷开环，提供了具有三个连续立体中心的高度取代的吡咯烷环体系。
• BRIDGED BICYCLIC AMINO THIAZINE DIOXIDE COMPOUNDS AS INHIBITORS OF BETA-SECRETASE AND METHODS OF USE THEREOF
  申请人：AMGEN INC.

  公开号：US20150038497A1

  公开（公告）日：2015-02-05

  The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A 4 , A 5 , A 6 , A 8 , R 1 , R 2 , R 3 , R 7 and n of Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and corresponding uses of the compounds and compositions for treatment of disorders and/or conditions related to A-beta plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. The invention further provides compounds of Formula II and sub-formula embodiments thereof, compounds of Formula III, intermediates and processes and methods useful for the preparation of compounds of Formulas I-III, and sub-Formulas thereof.

  本发明提供了一类新的化合物，用于调节β-分泌酶（BACE）活性。这些化合物具有一般的化学式I： 其中化学式I中的变量A4、A5、A6、A8、R1、R2、R3、R7和n，在本文中分别定义。该发明还提供了包括这些化合物的药物组合物，以及这些化合物和组合物用于治疗与A-beta斑块形成和沉积相关的疾病和/或症状的对应用途，这些疾病和症状是由BACE的生物活性引起的。这种由BACE介导的疾病包括阿尔茨海默病、认知缺陷、认知障碍、精神分裂症和其他中枢神经系统疾病。该发明还提供了化学式II和其亚式化合物、化学式III的化合物、中间体以及用于制备化学式I-III及其亚式化合物的化合物的制备的过程和方法。